Letters
Ranibizumab and bevacizumab
The cheaper drug, bevacizumab, should be referred to NICE
BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39128.708565.3A (Published 22 February 2007) Cite this as: BMJ 2007;334:381
- James P Raftery, professor of health technology assessment (raftery@soton.ac.uk)1,
- Andrew Lotery, professor of ophthalmology2
- 1University of Southampton, Southampton SO17 1SG
- 2Southampton Eye Unit, Southampton General Hospital, Southampton SO16 6YD
We think that Chakravarthy and Lim could have said more about the pricing of ranibizumab and bevacizumab.1 Both drugs are owned by a single company, Roche/Genentech, which has no intention of licensing the cheaper. The US price of ranibizumab is $1950 or roughly £1000 per injection. Monthly injections would cost £12 000 per patient. Bevacizumab, which is licensed for cancer treatment, could cost as little as £17 per injection, as the dosages used for eyes are minute compared with cancer. In the US, off-licence bevacizumab is estimated …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.